Vanda Pharmaceuticals | VNDA - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Akebia Therapeutics USD 265.42M 199K 2025-12
Alnylam Pharmaceuticals USD 133.44M 1.07M 2026-03
Anika Therapeutics USD 13.89M 532K 2025-12
Arrowhead Research USD 137.39M 1.69M 2025-12
AstraZeneca USD 1.55B 73K 2026-03
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Eli Lilly USD 943.5M 3.33M 2026-03
Enanta Pharmaceuticals USD 212K 1000 2023-12
Esperion Therapeutics USD 245.22M 39.79M 2025-12
Halozyme Therapeutics USD 118.52M 741K 2026-03
Heron Therapeutics USD 188.31M 4.99M 2025-12
Insmed USD 216.52M 2.27M 2026-03
J&J USD 2.41B 1.74M 2025-12
Lexicon Pharmaceuticals USD 363.47M 67K 2025-12
Ligand Pharmaceuticals USD 19.66M 19.64M 2025-09
Merck USD 2.47B 12.72M 2025-12
Minerva Neurosciences USD 1000 0 2024-09
Moderna USD 391M 2M 2025-09
Novartis USD 1.91B 10.64M 2025-12
Pfizer USD 5.7B 13M 2026-03
PTC Therapeutics USD 81.47M 1.54M 2025-12
Puma Biotechnology USD 5K 0 2024-06
Sanofi EUR 1.21B 8.25M 2026-03
Takeda JPY 1.58B 241K 2026-03
Teva Pharmaceutical Industries USD 1.16B 16.72M 2026-03
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Vanda Pharmaceuticals USD 58K 0 2024-12
Veracyte USD 79.79M 743K 2026-03